In adults with type 2 diabetes, higher-dose was linked to lower self-reported hunger and overeating tendencies, with greater weight loss tracking with those changes.
Evidence
Pre-specified exploratory analyses from a 36-week phase 2 trial in 275 adults with type 2 diabetes compared appetite and eating-inventory scores across placebo, dulaglutide 1.5 mg, and retatrutide 0.5 to 12 mg, with post-hoc correlations to weight change.
Caveat
These were self-reported exploratory outcomes, differences versus dulaglutide were less consistent, and the weight links came from post-hoc correlations rather than a primary clinical endpoint.
Simplified
AIMS: To determine whether adults with type 2 diabetes (T2D) treated with report greater changes in self-reported appetite, , and compared to placebo or dulaglutide and to examine associations with weight change.
MATERIALS AND METHODS: These pre-specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once-weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.5, 4, 8, or 12 mg in 275 adults with T2D. Changes from baseline with retatrutide were compared to those with placebo and dulaglutide. Post-hoc correlations between changes in body weight and Appetite VAS/EI scores were also examined.
RESULTS: Compared with placebo, participants who received retatrutide ≥4 mg reported greater reductions from baseline in overall appetite, hunger, and prospective food consumption (l at Week 24 (all p <0.05)). Differences versus dulaglutide were less consistent. Improvements from baseline versus placebo in EI Perceived Hunger and Disinhibition were greater in participants who received retatrutide 8 and 12 mg at Weeks 24 and 36. Dietary Restraint increased from baseline versus placebo only in participants who received retatrutide 12 mg at Week 36 (all p <0.05). Reductions in Perceived Hunger and Disinhibition, and increases in Dietary Restraint were significantly correlated with reductions in body weight at Week 36 (r = 0.28, r = 0.36, and r = 0.31, respectively).
CONCLUSIONS: Perceived hunger and tendency to overeat (disinhibition) were reduced with higher doses of retatrutide, compared with placebo. Greater weight reduction was associated with decreased perceived hunger and disinhibition and increased dietary restraint.
PLAIN LANGUAGE SUMMARY: WHAT IS THE CONTEXT AND PURPOSE OF THIS RESEARCH STUDY?: Retatrutide is a new treatment currently being developed for people with obesity and people with type 2 diabetes. This study compared the changes in appetite and eating behaviours of adults with T2D who were treated with retatrutide, dulaglutide (an alternative treatment), or placebo (i.e., no treatment). We examined changes in feelings of hunger, satisfaction and fullness, the desire to eat certain types of foods (e.g., sweet, salty or fatty foods), the tendency to overeat (e.g., when stressed), and conscious efforts to limit food intake. We also examined the potential link between changes in appetite or eating behaviours and changes in weight during retatrutide treatment. WHAT WAS DONE?: Adults with type 2 diabetes who participated in this trial completed two questionnaires that measured their eating habits at several time points during the 36-week period in which they received treatment. The questionnaire responses of people who received retatrutide each week (1-4 different doses) were compared with the responses of people who received no treatment (i.e., placebo) and of people who received dulaglutide treatment. Any potential links between the amount of weight reduction people experienced while receiving treatment during the study and their questionnaire responses were also examined. WHAT WERE THE MAIN RESULTS?: This study showed that adults with type 2 diabetes who received higher doses of retatrutide reported being less likely to feel hungry or overeat compared to those who received no treatment (i.e., placebo) or those who received dulaglutide. On average, people who experienced greater weight reduction also reported being less hungry and less likely to overeat. WHAT IS THE ORIGINALITY AND RELEVANCE OF THIS STUDY?: This is the first study to assess changes in appetite and eating behaviours of adults with type 2 diabetes who received retatrutide. Our results suggest that enhanced modification of eating behaviours with retatrutide may assist with weight reduction in adults with type 2 diabetes.
Key numbers
10.7
Decrease in Overall Appetite
LSM difference in overall at Week 8 for 4 mg vs. placebo.
2.6
Reduction in Score
LSM difference for 12 mg vs. placebo at Week 36.
3.7
Increase in Score
LSM change in for 12 mg vs. placebo at Week 36.
Full Text
We can’t show the full text here under this license.
C.K., K.S.B., J.L.P, I.G., J.L., M.L.H. and T.C. are full‐time employees and minor stockholders of Eli Lilly and Company. S.W. works as a consultant for Eli Lilly and Company. C.K.M. has been the primary investigator and co‐investigator on research contracts from Lilly, which were paid to his institution. His institution has also received funds via contracts with Lilly to provide advice on patient‐reported outcomes when designing studies. These agreements were not related to the current work. Lilly manufactures the drug assessed in this study.
